Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Amortization - Intangibles history runs 17 years deep, the most recent figure standing at $172.3 million for Q1 2026.

• In Q1 2026, Amortization - Intangibles rose 11.59% year-over-year to $172.3 million; the TTM figure through Mar 2026 stood at $672.5 million (up 7.43% YoY), while the FY2025 annual figure was $654.7 million, up 4.36% from the prior year.
• Amortization - Intangibles was $172.3 million for Q1 2026 at Jazz Pharmaceuticals, up from $169.7 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $172.3 million in Q1 2026 to a low of $137.4 million in Q4 2022.
• Historically, Amortization - Intangibles has averaged $156.6 million across 5 years, with a median of $155.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Amortization - Intangibles surged 152.37% in 2022, then fell 12.96% in 2023.
• A 5-year view of Amortization - Intangibles shows it stood at $137.4 million in 2022, then rose by 10.31% to $151.6 million in 2023, then grew by 4.85% to $158.9 million in 2024, then increased by 6.82% to $169.7 million in 2025, then advanced by 1.51% to $172.3 million in 2026.
• The last three Amortization - Intangibles figures came in at $172.3 million (Q1 2026), $169.7 million (Q4 2025), and $168.4 million (Q3 2025), per Business Quant data.